Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will India’s Sun Rise On Stada? Bankers, Analysts Divided On Risks, Benefits

This article was originally published in PharmAsia News

Executive Summary

Stada’s financial woes may not be primary factors for Sun to bid but analysts reason there may be value accretive points.


Related Content

Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
Germany's Discount Contracts Are Changing The Pharma Market Landscape


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts